What is denosumab-qbde?

Denosumab-qbde is a human IgG2 monoclonal antibody that binds to human RANKL. Denosumab-qbde has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells. Xtrenbo (denosumab-qbde) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution for subcutaneous use. Each single-dose vial contains 120 mg denosumab-qbde, glacial acetic acid (1.8375 mg), polysorbate 20 (0.17 mg), sorbitol (78.2 mg), Water for Injection (USP). Sodium hydroxide may be added to adjust pH to approximately 5.2.

Can you take denosumab-qbde with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run denosumab-qbde against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What brand names is denosumab-qbde sold under?

We track 2 denosumab-qbde-containing products in the U.S.: Enoby and Xtrenbo. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

What forms does denosumab-qbde come in?

Across the brands we track, denosumab-qbde is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic denosumab-qbde?

We do not currently list a generic-labelled denosumab-qbde product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

Denosumab-Qbde: uses, dosing, side effects & brands

Denosumab-Qbde is a medicine sold in the U.S. under 2 brand and generic names, for postmenopausal osteoporosis. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesHow we research

Key facts

Treats: Postmenopausal Osteoporosis
Available as: Injectable
Sold as: 2 products — Enoby and Xtrenbo
Prescription?: Prescription only
Generic available?: Not in our catalog

How denosumab-qbde is dosed

From the FDA label for Enoby (application BLA761439). Other denosumab-qbde products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

Xtrenbo should be administered by a healthcare provider. ( 2.1 ) Xtrenbo is intended for subcutaneous route only and should not be administered intravenously, intramuscularly, or intradermally. ( 2.1 ) Multiple Myeloma and Bone Metastasis from Solid Tumors: Administer 120 mg every 4 weeks as a subcutaneous injection in the upper arm, upper thigh, or abdomen. ( 2.2 ) Giant Cell Tumor of Bone: Administer 120 mg every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. Administer subcutaneously in the upper arm, upper thigh, or abdomen. ( 2.3 ) Administer calcium and vitamin D as necessary to treat or prevent hypocalcemia. ( 2.2 , 2.3 ) Hypercalcemia of Malignancy: Administer 120 mg every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. Administer subcutaneously in the upper arm, upper thigh, or abdomen. ( 2.4 ) 2.1 Important Administration Instructions Xtrenbo should be administered by a healthcare provider. Xtrenbo is intended for subcutaneous route only and should not be administered intravenously, intramuscularly, or intradermally. 2.2 Multiple Myeloma and Bone Metastasis from Solid Tumors The recommended dose of Xtrenbo is 120 mg administered as a subcutaneous injection every 4 weeks in the upper arm, upper thigh, or abdomen. Administer calcium and vitamin D as necessary to treat or prevent hypocalcemia…

Denosumab-Qbde side effects

The following adverse reactions are discussed below and elsewhere in the labeling: Hypersensitivity [see Warnings and Precautions (5.2) ] Hypocalcemia [see Warnings and Precautions (5.3) and Use in Specific Populations (8.6) ] Osteonecrosis of the Jaw [see Warnings and Precautions (5.4) ] Atypical Subtrochanteric and Diaphyseal Femoral Fracture [see Warnings and Precautions (5.5) ] Hypercalcemia following treatment discontinuation in patients with giant cell tumor of bone and in patients with growing skeletons [see Warnings and Precautions (5.6) and Use in Specific Populations (8.4) ] Multiple vertebral fractures (MVF) following treatment discontinuation [see Warnings and Precautions (5.7) ] Bone Metastasis from Solid Tumors: Most common adverse reactions (≥ 25%) were fatigue/asthenia, hypophosphatemia, and nausea. ( 6.1 ) Multiple Myeloma: Most common adverse reactions (≥ 10%) were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache. ( 6.1 ) Giant Cell Tumor of Bone: Most common adverse reactions (≥ 10%) were arthralgia, headache, nausea, back pain, fatigue, and pain in extremity. ( 6.1 ) Hypercalcemia of Malignancy: Most common adverse reactions (> 20%) were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrhea. ( 6.1 ) To report…

Every denosumab-qbde product we track (2)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Denosumab-Qbde products
#	Drug	Rating	Type	Form	Generic?	Typical price
1	Enoby	70/100	Prescription	Injectable	—	—	View →
2	Xtrenbo	70/100	Prescription	Injectable	—	—	View →

Frequently asked questions

What is denosumab-qbde?: Denosumab-qbde is a human IgG2 monoclonal antibody that binds to human RANKL. Denosumab-qbde has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells. Xtrenbo (denosumab-qbde) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution for subcutaneous use. Each single-dose vial contains 120 mg denosumab-qbde, glacial acetic acid (1.8375 mg), polysorbate 20 (0.17 mg), sorbitol (78.2 mg), Water for Injection (USP). Sodium hydroxide may be added to adjust pH to approximately 5.2.
Can you take denosumab-qbde with other medicines?: It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run denosumab-qbde against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is denosumab-qbde sold under?: We track 2 denosumab-qbde-containing products in the U.S.: Enoby and Xtrenbo. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does denosumab-qbde come in?: Across the brands we track, denosumab-qbde is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic denosumab-qbde?: We do not currently list a generic-labelled denosumab-qbde product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.